BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $119 at Deutsche Bank

August 3, 2017 8:52 AM EDT

Deutsche Bank raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $119.00 (from $118.00) while maintaining a Buy rating.

Analyst Andrew Peters commented, "Todays results and hemophilia update continue to support our bullish view on BioMarins diversified and high-growth portfolio. Second quarter... More